Evidence map›Paper›PMID 40563524›Full record

ArticleBiomolecules2025

Pre-Amplification of Cell-Free DNA: Balancing Amplification Errors with Enhanced Sensitivity.

Wei Yen Chan, Ashleigh Stewart, Russell J Diefenbach, Elin S Gray, Jenny H Lee, Richard A Scolyer, Georgina V Long, Helen Rizos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei Yen ChanFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0002-8657-2995
Ashleigh StewartFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0001-5676-1982
Russell J DiefenbachFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0002-8433-4336
Elin S GrayCentre for Precision Health, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-8613-3570
Jenny H LeeFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0001-8844-3444
Richard A ScolyerMelanoma Institute of Australia, The University of Sydney, Sydney, NSW 2065, Australia.ORCID 0000-0002-8991-0013
Georgina V LongMelanoma Institute of Australia, The University of Sydney, Sydney, NSW 2065, Australia.ORCID 0000-0001-8894-3545
Helen RizosFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0002-2094-9198

Funding

CLEARbridge Foundation CLEARbridge FoundationMedical Research Future Fund 2035430United States Department of Defense W81XWH-22-1-0731
6 · The paper itself

Abstract

Circulating tumour DNA (ctDNA) is a promising biomarker for personalised oncology. However, its clinical utility is limited by detection sensitivity, particularly in early-stage disease. T-Oligo Primed Polymerase Chain Reaction (TOP-PCR) is a commercial amplification approach utilising an efficient "half-adapter" ligation design and a single-primer-based PCR strategy. This study evaluated the clinical value and application of cell-free DNA (cfDNA) pre-amplification. cfDNA amplification with TOP-PCR preserved DNA size profiles and resulted in a 22 bp size increase due to the half-adaptor ligation. Gene target amplification rates varied, showing lower efficiency for the GC-rich TERT promoter amplicon and higher efficiency for the

Indexed as

Cell-Free Nucleic AcidsCirculating Tumor DNAPolymerase Chain ReactionBiomarkers, TumorHumansMutationNeoplasmsProto-Oncogene Proteins B-rafTelomeraseTumor Suppressor Protein p53Biomarkers, TumorBRAF protein, humanCell-Free Nucleic AcidsCirculating Tumor DNAProto-Oncogene Proteins B-rafTelomeraseTERT protein, humanTumor Suppressor Protein p53circulating tumour DNAdetection sensitivitymelanoma

Identifiers

PMID40563524
PMCPMC12191314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.